Large pharmaceutical companies say allowing Medicare to negotiate lower drug prices will stifle innovation in drug development. Read a new op-ed in Harvard Business Review to find out why that’s not so.
2016Access To Care
14%
n/a
16%
n/a
n/a
7%
17%
7%
n/a
n/a
n/a
n/a
8%
18%
10%
n/a
8%
22%
n/a
33%
2016 Commonwealth Fund International Health Policy Survey
Access barrier because of cost defined as at least one of the following: Did not fill/skipped prescription, did not visit doctor with medical problem, and/or skipped medical treatment or test.
